Novavax hopes to file for US vaccine approval in 2nd quarter of 2021

Washington (AFP) – US biotech company Novavax said Monday it hopes to file for British approval of its Covid-19 vaccine at the start of the second quarter of 2021, and to do the same soon after in the United States. The company has no assurance that US authorities will agree to consider the request, which currently is based on results from Phase 3 clinical trials led in the Britain. Similar trials are still ongoing in the United States. The data will hopefully be presented to the British health regulator (MHRA) “by early second quarter 2021,” Novavax said in a statement, on the occasion of the…

Read More

HEDGE accordingly